We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 51

Snapshot of Sunshine rules in EU countries for the pharmaceutical industry part 1 - June 2014

  • McDermott Will & Emery
  • -
  • European Union, United Kingdom
  • -
  • June 12 2014

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. In 2013

The new EU clinical trials regulation aims at harmonization and transparency

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • October 20 2014

On June 16, 2014, Reg. (EU) No. 5362014 on Clinical Trials on Medicinal Products for Human Use (Regulation) has entered into force. Once it becomes

What did you say? $31 million awarded for infringement of hearing aid patent

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • November 29 2012

In a case involving the alleged infringement of two patents related to hearing aids, one of which was found under judgment as a matter of law (JMOL) to not be infringed

Repackaging and parallel import of pharmaceutical products

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • May 22 2007

On 27 April 2007, the European Court of Justice (the “ECJ”) handed down yet another decision in the case of Boehringer Ingelheim & others v Swingward Ltd and Dowelhurst Ltd, Case C-34804 (“Boehringer II”

Navigating the evolving regulation and commercialization of stem cell research

  • McDermott Will & Emery
  • -
  • European Union, USA
  • -
  • March 22 2012

Interested parties that can successfully navigate the evolving regulation of stem cell research stand to gain significant scientific and commercial advantage

European Commission fines pharmaceutical companies for Citalopram pay-for-delay agreements

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • June 30 2013

On 19 June 2013, the European Commission announced a fine of 93.8 million for H. Lundbeck AS (Lundbeck) and a further 52.2 million of fines levied

EPO Enlarged Board of Appeal invites the public to determine whether stem cells are contrary to morality

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • July 30 2008

On 24 and 25 June 2008, in a public hearing on Wisconsin Alumni Research Foundation (WARF) Stem Cell patent application (G-0206), the European Patent Office (EPO) took the usual step of asking the public to assist it in making a determination regarding a patent application involving an invention in the controversial area of stem cell patenting

Celltech: what’s in a name?

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • May 22 2007

Celltech had filed an application with the Office of Harmonization for the Internal Market (“OHIM”) for registration of the word mark “Celltech” (combination of two terms ‘cell’ and ‘technology’) as a Community Trade Mark for goods and services in classes 5,10 and 42: ‘pharmaceutical, veterinary and sanitary preparations, compounds and substances’, ‘surgical, medical, dental and veterinary apparatus and instruments’ and ‘R&D services, consultancy services’

Controlling and processing data in EU clinical trials

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • November 22 2010

The legal regime for the conduct of clinical trials of medicinal products for human use in the European Union is set out in Directive 200120EC (the Clinical Trials Directive

EC introduces major changes to medical device regulation

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • December 17 2012

The European Commission has issued two proposals that, if approved, will fundamentally amend EU law on medical devices and in vitro diagnostics